Sort
15,842 grants matching “pancreatic cancer”
Prospective Cohort Collaborative in Pancreatic Cancer Epidemiology & Pathogenesis
$928,555Charles S Fuchs · Dana-Farber Cancer Inst · R01 · FY2007 · CA
Using markers to improve pancreatic cancer screening and surveillance
$927,908Michael G. Goggins · Johns Hopkins University · U01 · FY2019 · CA
Biological Functions of Chromosomal Proteins
$927,598Michael Bustin · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Evolution of Primary and Resistant Solid Tumors
$925,724Ronald Anthony Depinho · Dana-Farber Cancer Inst · U01 · FY2007 · CA
Altered metabolism and machine learning for pancreatic cancer early detection
$925,639Brian Matthew Wolpin · Dana-Farber Cancer Inst · U01 · FY2022 · CA
Development of a TRAIL-based therapy for alcohol related chronic pancreatitis
$924,849Victor V Roschke · Theraly Fibrosis, Inc. · U44 · FY2017 · AA
Mesothelin-targeted immunotoxins in Pancreatic Cancer
$924,682Christine Alewine · Division Of Basic Sciences - Nci · ZIA · FY2017 · CA
Cancer Gene Discovery to Identify Targetable Targets
$924,000Carlo M Croce · Ohio State University · R35 · FY2020 · CA
Cancer Gene Discovery to Identify Targetable Targets
$924,000Carlo M Croce · Ohio State University · R35 · FY2017 · CA
Cancer Gene Discovery to Identify Targetable Targets
$924,000Carlo M Croce · Ohio State University · R35 · FY2015 · CA
Cancer Gene Discovery to Identify Targetable Targets
$924,000Carlo M Croce · Ohio State University · R35 · FY2016 · CA
Cancer Gene Discovery to Identify Targetable Targets
$924,000Carlo M Croce · Ohio State University · R35 · FY2018 · CA
Exosome-based microRNA biomarkers for Non-invasive and Early Detection of Pancreatic Cancer
$923,881Ajay Goel · Beckman Research Institute/City Of Hope · U01 · FY2023 · CA
Clinical Production and IND enabling Studies for PSCA Minibody Imaging in Pancrea
$923,853Bradley T Wyman · Imaginab, Inc. · R44 · FY2012 · CA
Molecular strategies for early detection and targeting of cancer
$923,001Tannishtha Reya · Columbia University Health Sciences · R35 · FY2025 · CA
Participant Engagement Unit
$922,915Andrew Louis Sussman · University Of New Mexico Health Scis Ctr · U2C · FY2025 · CA
New Ways of Targeting K-Ras
$922,279Frank Patrick McCormick · University Of California, San Francisco · R35 · FY2022 · CA
Cellular Basis Of Action Of Gastrointestinal Peptides/Growth factors
$922,054Robert Jensen · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2024 · DK
Targeting undruggable RAS for cancer treatment
$921,017Channing J Der · Univ Of North Carolina Chapel Hill · R35 · FY2021 · CA
Using ex vivo, in vivo models and patient mutations to interrogate pancreatic exocrine-endocrine cross talk
$919,535Rohit N. Kulkarni · Joslin Diabetes Center · U01 · FY2023 · DK
Ligand-Directed KRAS G12V Mutant-Specific Therapeutics
$919,020Lyla Stanland · Enfuego Therapeutics Inc. · R44 · FY2025 · CA
Ligand-Directed KRAS G12V Mutant-Specific Therapeutics
$919,020Lyla Stanland · Enfuego Therapeutics Inc. · R44 · FY2024 · CA
New Ways of Targeting K-Ras
$918,748Frank Patrick McCormick · University Of California, San Francisco · R35 · FY2017 · CA
Targeting undruggable RAS for cancer treatment
$918,610Channing J Der · Univ Of North Carolina Chapel Hill · R35 · FY2020 · CA
Pathways that Suppress or Accelerate Premalignant Progression of Squamous Cancer
$917,731Stuart H. Yuspa · Division Of Basic Sciences - Nci · ZIA · FY2021 · CA